Andrew Gdowski, DO
Hematology & Oncology · Dallas, TXNPI 1508362179
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,908 of the $3,875 with a category attached, or 75.1%. It is spread thinly across 39 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,701, more than ten times the $100 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 119 payments — averaging $32.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$829
- Daiichi Sankyo Inc.$332
- Regeneron Healthcare Solutions, Inc.$240
- Tempus AI, Inc$210
- Johnson & Johnson$197
- AstraZeneca$193
- plus $2K from 33 others
What the payments were for
- Food & beverage$2,90875%
- Education$2697%
- Other$69818%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $829 |
| Daiichi Sankyo Inc. | 8 | $332 |
| Regeneron Healthcare Solutions, Inc. | 4 | $240 |
| Tempus AI, Inc | 8 | $210 |
| Johnson & Johnson | 5 | $197 |
| AstraZeneca(2 entities) | 8 | $193 |
| Exelixis Inc. | 2 | $179 |
| Pfizer | 9 | $175 |
| E.r. Squibb & Sons, L.L.C. | 8 | $139 |
| Incyte Corporation | 2 | $129 |
| Merck | 5 | $109 |
| Gilead | 4 | $96 |
| Astellas Pharma US Inc | 4 | $94 |
| Bristol Myers Squibb | 3 | $93 |
| Seagen Inc. | 1 | $79 |
| Eisai Inc. | 3 | $67 |
| Array Biopharma Inc | 4 | $65 |
| GSK | 3 | $61 |
| Jazz Pharmaceuticals Inc. | 2 | $59 |
| Bayer | 2 | $47 |
| Tersera Therapeutics LLC | 2 | $37 |
| Novocure Inc. | 1 | $33 |
| Accord Healthcare, Inc. | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $30 |
| Beigene USA, Inc. | 1 | $29 |
| Pharmaessentia USA Corporation | 1 | $29 |
| Puma Biotechnology, Inc. | 2 | $28 |
| ADC Therapeutics America, Inc. | 1 | $27 |
| Adaptive Biotechnologies Corporation | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $24 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $23 |
| Geron Corporation | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Syndax Pharmaceuticals, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,875 in reported general payments places this provider in the 50th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.